Wilmington, DE, United States of America

Adam Shilling

This inventor holds 3 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: Incyte Corporation, Incyte Holdings Corporation. Active years: 2013-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Adam Shilling. Retrieved from https://idiyas.com/inventor/adam-shilling

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 3

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 7.0

ph-index = 3

Forward Citations = 198(Granted Patents)

Company Filing History:

Incyte Holdings Corporation

patents

where one patent can have more than one assignee

Years Active: 2013-2016

Loading Chart...

3 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9512161 - Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (2016-12-06),

2. 8748401 - Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (2014-06-10),

3. 8486902 - Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (2013-07-16),

Title: Adam Shilling: Innovator in Pharmaceutical Chemistry

Introduction

Adam Shilling is a notable inventor based in Wilmington, DE (US). He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 3 patents. His work focuses on the development of innovative chemical compounds that have potential therapeutic applications.

Latest Patents

Among his latest patents are the hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile. This invention provides valuable derivatives that could enhance the efficacy of treatments in various medical conditions. The detailed description of these compounds highlights their potential in advancing pharmaceutical research.

Career Highlights

Adam has worked with prominent companies in the pharmaceutical industry, including Incyte Corporation and Incyte Holdings Corporation. His experience in these organizations has allowed him to collaborate with leading experts and contribute to groundbreaking research in drug development.

Collaborations

Throughout his career, Adam has collaborated with talented individuals such as James David Rodgers and Argyrios George Arvanitis. These partnerships have fostered innovation and have been instrumental in the advancement of his research projects.

Conclusion

Adam Shilling is a distinguished inventor whose work in pharmaceutical chemistry continues to impact the industry. His innovative patents and collaborations reflect his commitment to advancing medical science.

Profile summary based on public USPTO records.